The leading parameters that define treatment recommendations in early breast cancer are
oestrogen-receptor, progesterone-receptor, and human epidermal growth-factor status …

Triple-negative breast cancer (TNBC) is defined as a type of breast cancer with lack of
expression of estrogen receptor (ER), progesterone receptor (PR) and HER2 protein. The …

Abstract The 13th St Gallen International Breast Cancer Conference (2013) Expert Panel
reviewed and endorsed substantial new evidence on aspects of the local and regional …

Abstract The 12th St Gallen International Breast Cancer Conference (2011) Expert Panel
adopted a new approach to the classification of patients for therapeutic purposes based on …

Uncontrolled proliferation is a hallmark of cancer. In breast cancer, immunohistochemical
assessment of the proportion of cells staining for the nuclear antigen Ki67 has become the …

Background Gene expression profiling of breast cancer has identified two biologically
distinct estrogen receptor (ER)-positive subtypes of breast cancer: luminal A and luminal B …

The proliferation marker Ki-67 is one of the most controversially discussed parameters for
treatment decisions in breast cancer patients. The purpose of this study was to evaluate the …

Systemic therapies for operable breast cancer patients have improved outcomes and have
thus become standard treatments. Recently, new molecular target drugs and regimens are …

Breast cancer (BC) is a heterogeneous disease, encompassing a diverse spectrum of
tumours with varying morphological, biological, and clinical phenotypes. Although tumours …

Purpose The 21-gene Recurrence Score (RS) assay is a validated prognostic/predictive tool
in early hormone receptor–positive breast cancer (BC); however, only a few prospective …